ORIGINAL ARTICLE

Genetic markers for preeclampsia in Peruvian women

Marcadores genéticos de preeclampsia en mujeres peruanas

José Pacheco-Romero[1]* Oscar Acosta Conchucos[2]* Doris Huerta Canales[1] Santiago Cabrera Ramos[1] Marlene Vargas Chávez[1] Pedro Mascaro Sánchez[1] Moisés Huamán Guerrero[1] José Sandoval Paredes[1] Rudy López Gabriel[1] Julio Mateus[1,3] Enrique Gil Guevara[1] Enrique Guevara Rios[1] Nitza Butrica Ferré[1] Diana Catari Soto[1] David Bellido Yarlequé[1] Gina Custodio González[1] Andrea Naranjo Adonaire[1]

jpachecor@unmsm.edu.pe

1 Universidad Nacional Mayor de San Marcos, Faculty of Medicine. Medicina y Genética Molecular Materno Perinatal-MEGEMAPE Research Group, Lima, Peru. 2 Universidad Nacional Mayor de San Marcos, Faculty of Pharmacy and Biochemistry, Lima, Peru. 3 Atrium Health, Charlotte, North Carolina, USA

* These authors contributed equally to this work.

Abstract

Background:

Preeclampsia is a multiorgan disorder associated with maternal and perinatal morbi-mortality. In Peru, incidence is 10% and accounts for 22% of maternal deaths. Genome and genetic epidemiological studies have found an association between preeclampsia and genetic polymorphisms.

Objective:

To determine the association of the vascular endothelial growth factor (VEGF) +936 C/T and +405 G/C, interleukine-6 (IL-6) -174 G/C, IL-1β-511 C/T, Apo A-1-75 G/A, Apo B-100 2488 C/T (XbaI) polymorphisms with preeclampsia in pregnant Peruvian women.

Methods:

Were included preeclamptic and healthy (control) pregnant women. Maternal blood samples were subjected to DNA extraction, and molecular genetic analysis was conducted using the PCR-RFLP technique and following a specific protocol for each gene. Allele and genotypic frequencies in the cases and controls were compared.

Results:

No association was found between the VEGF+936C/T and VEGF+405 polymorphisms and preeclampsia. The frequencies of the GG genotypes and the G allele of the -174 G/C polymorphism in the IL6 gene in preeclamptic and controls showed significant differences, with higher frequencies in cases. For the -511 C/T polymorphism of the IL-1β gene, no significant differences were found in the frequencies of TT genotypes compared with CT+CC. The genotypes and alleles of the Apo-A1-75 G/A and Apo-B100 XbaI variants showed no significant differences between cases and controls.

Corresponding author:

José Pacheco-Romero, MD, MSc, PhD, FACOG. Faculty of Medicine, Universidad Nacional Mayor de San Marcos Lima, Peru. Phone: 51 1 372 3555 - Cell: 51 1 999 481 979. **Email: jpachecor@ unmsm.edu.pe**

Conclusion:

No association was found between the studied genetic markers and preeclampsia. However, in the -174G/C polymorphism of the IL-6 gene, significant differences were found mainly in the GG genotype and G allele.

Resumen

Antecedentes:

La preeclampsia es un trastorno multiorgánico asociado con la morbi-mortalidad materna y perinatal. En el Perú, su incidencia es del 10% y causa el 22% de las muertes maternas. Se encontró una asociación entre la preeclampsia y ciertos polimorfismos.

Objetivo:

Determinar asociación entre los polimorfismos genéticos del factor de crecimiento endotelial vascular (VEGF) +936 C/T y +405 G/C, interleucina-6 (IL-6) -174G/C, IL-1β -511 C/T, Apo A-1 -75 G/A, Apo B-100 2488 C/T (Xbal), y preeclampsia en gestantes peruanas.

Métodos:

Se incluyeron gestantes preeclámpticas y sanas (controles). Las muestras de sangre fueron procesadas para extracción del ADN, y el análisis se realizó con la técnica PCR-RFLP con protocolos específicos para cada gen y confirmación con secuenciamiento Sanger. Se compararon las frecuencias alélicas y genotípicas en los casos (preeclampsia) y los controles.

Resultados:

No se halló asociación entre los polimorfismos VEGF+936-C/T y VEGF+405 y la preeclampsia. Las frecuencias de los genotipos GG y el alelo G del polimorfismo -174-G/C en el gen IL6 en preeclámpticas y controles, mostraron diferencias significativas, con frecuencias más altas en los casos. Para el polimorfismo -511-C/T del gen IL-1β, no se encontraron diferencias significativas en las frecuencias de genotipos TT comparados con CT+CC. Los genotipos y alelos de las variantes Apo-A1-75-G/A y Apo-B100 Xbal no mostraron diferencias significativas entre los grupos

Conclusión:

No se encontró asociación entre los marcadores genéticos estudiados y la preeclampsia. Sin embargo, el polimorfismo -174-G/C en el gen IL6 mostró diferencias significativas principalmente en el genotipo GG y el alelo G.

Remark

1)Why was this study conducted?

Preeclampsia is a multiorgan disorder that is significantly associated with maternal and perinatal morbidity and mortality. Preeclampsia is defined by the presence of new-onset hypertension and proteinuria in women who are at least 20 weeks pregnant. The etiology of preeclampsia remains unknown; its clinical presentation and dynamics vary, and no method can predict its occurrence. In Peru, preeclampsia incidence is greater than 10%, and it accounts for 22% of maternal deaths. Genome and genetic epidemiologial studies have found an association of preeclampsia and certain gene polymorphisms and variants. In this study, we evaluated the susceptibility gene polymorphisms related to endothelial function, angiogenesis, immunologic and inflammatory processes, and metabolic syndrome in Peruvian preeclamptic women.

2) What were the most relevant results of the study?

No association was found between the studied genetic markers and preeclampsia. However, in the -174G/C polymorphism of the IL6 gene, significant differences mainly in the GG genotype and G allele were found, wherein the frequencies were higher in the cases than in the controls.

3) What do these results contribute?

This study contributes to our knowledge of the genetic factors associated with preeclampsia, an emergent research topic in Peru. High genetic mixing and other factors may partially explain the conflicting findings for the Peruvian population.

Introduction

Hypertension is the most frequent medical complication of pregnancy [1], and the most severe clinical presentation of hypertensive disorders of pregnancy is preeclampsia, a condition that is significantly associated with maternal and perinatal morbidity and mortality.

Preeclampsia is the leading cause of maternal death in the western world. It is a multiorgan disorder involving new-onset hypertension (>140/90 mm Hg) and proteinuria in women who are at least 20 weeks pregnant [2]. The clinical presentation and dynamics of preeclampsia are variable; for instance, hypertension and proteinuria may not always be present [3]. In the absence of proteinuria, preeclampsia diagnosis is based on the occurrence of hypertension accompanied by low platelet count (below 100,000/mL), abnormal liver function (indicated by serum transaminase levels that are twice the normal concentrations), kidney failure (indicated by serum creatinine level exceeding 1.1 mg/dL or by serum creatinine levels that are twice the levels in the absence of other renal diseases), pulmonary edema, or de novo presentation of cerebral or visual alterations [2].

Preeclampsia affects 3% to 8% of pregnant women, depending on the population and region being studied and on the definition of preeclampsia being used [4,5]. In Peru, preeclampsia incidence is greater than 10% in various regions [3] and it accounts for 22% of all maternal deaths.

The common factors associated with preeclampsia development in developed countries are obesity, insulin resistance and hyperlipidemia, whereas in developing countries, the associated factors are ethnicity, poor nutritional habits, subclinical infections, and other socioeconomic characteristics [6].

The etiology of preeclampsia remains unknown. However, it has been found that genetic factors cause a defective immune adaptation [7], which in turn leads to inadequate trophoblast invasion and inappropriate placenta development. Abnormal endometrial cytotrophoblast

infiltration generates arterial disorders, such as loss of elasticity that affects vascular remodeling and impairs the fetus's blood supply [8,9]. Placental ischemia and hypoxia as well as oxidative stress and endotheliosis then develop [6], compromising the placenta and important maternal organs and systems. Oxidative stress stimulates the syncytiotrophoblast to release proinflammatory cytokines, exosomes, antiangiogenic factors, and cell-free fetal DNA into the maternal circulation [4,10].

Complications can emerge at any point during pregnancy, frequently surreptitiously and severely. Prior to the development of a clinical disease, vasospasm, activation of the coagulation cascade, and reduction in plasma volume occur. There are more harmful effects when preeclampsia appears early, including intrauterine growth retardation (IUGR) and prematurity [3]. Moreover, placental senescence is accelerated [11], the concentration of pro-inflammatory cytokines, cell-free DNA, leptin, placental apoptotic debris and soluble fms-like tyrosine kinase 1 (sFLT1) in maternal blood increases, and placental growth factor (PlGF) levels decrease [12].

There is no method that can predict the onset of preeclampsia, and there is no cure for this condition other than the delivery of the fetus and the placenta. Preeclampsia usually resolves soon after delivery. However, epidemiological studies have associated preeclampsia with metabolic, cardiovascular and cerebral disorders [2,13-15] that will appear later in the mother and child, and this association has a great impact on disability and heathcare expenditure eventually [15-17].

Genome and genetic epidemiology studies have found an association between preeclampsia and certain genes [7,18], polymorphisms and other molecular and inflammatory markers [7,8,19,20]. Thus, detecting these biomarkers early in gestation will allow us to predict and manage preeclampsia properly.

Several pro- and anti-angiogenic proteins are produced in the placenta from the beginning of pregnancy; these substances play a role in endothelial dysfunction and the risk of preeclampsia [9,20]. The most important angiogenic factors [21,22] include the vascular endothelial growth factor (VEGF) [22] and the placental growth factor (PGF) [23]. Antiangiogenic substances are abundantly expressed in preeclampsia and cause maternal endothelial cell dysfunction and damage [1,3,24], which have negative consequences to a mother and her fetus. The genes encoding for the important antiangiogenic factors include the soluble tyrosinase-like factor (sFLT-1) gene, the VEGF soluble Fms-like tyrosine kinase -1 (VEGFR-1) [25] gene, and the endothelin-1 gene polymorphisms [26,27].

Due to the high prevalence of preeclampsia in Peru and considering that oxidative stress induces the syncytiotrophoblast to release pro-inflammatory cytokines, exosomes, anti-angiogenic factors, and cell-free fetal DNA into maternal circulation [4,10], we decided to characterize some of these biomarkers in preeclamptic Peruvian women and verify whether these biomarkers can be applied to predict, prevent and manage preeclampsia among Peruvian women. We studied some genes and polymorphisms involved in preeclampsia, including the VEGF +936C/T and +405G/C polymorphisms, interleukin-6 (IL-6) gene polymorphisms, IL-1β gene -511C/T polymorphism [28], and polymorphisms of both the Apo A-1 and Apo B-100 genes, in preeclamptic and healthy Peruvian pregnant women. Our findings increase our knowledge of the genetic factors associated with preeclampsia, an emergent research topic in Peru.

Materials and Methods

This study is an observational associative case-control study performed between 2012 and 2018. The participating institutions were the Institute of Clinical Investigations and the Biochemistry and Nutrition Research Center of the Faculty of Medicine, National University of San Marcos, Lima, Peru. Subjects were recruited from the Hospital Docente Madre-Niño San Bartolomé, a public institution that is managed by the Peruvian Ministry of Health.

Table 1. Number of preeclamptic women and controls included in the study.

Gene	Polymorphism	Preeclampsia	Control	Total
VEGF	+936 C/T	45	49	94
	+405 G/C	39	45	84
IL-6	-174 G/C	20	39	59
IL1β	-511 C/T	49	50	99
Apo A-1	-75 G/A	47	45	92
Apo B-100	2 488 C/T (Xbal)	47	45	92

A preeclamptic woman was defined as a pregnant woman with a blood pressure of >140/90 mm Hg and proteinuria of ≥300 mg/24 h (>1+ dipstick) according to the International Federation of Gynecology and Obstetrics classification, which was updated in the year 2000 [1].

The sampling method was non-probabilistic (for convenience). The inclusion criteria for the preeclampsia group were as follows: pregnant women aged ≥18 years who had been diagnosed with severe preeclampsia in the second half of pregnancy as confirmed by clinical and laboratory data and who had signed an informed consent. Pregnant women without proteinuria or those with chronic hypertension, diabetes, and other medical conditions as well as those with incomplete information were excluded. For the control group, the inclusion criteria were as follows: pregnant women aged ≥18 years who were apparently healthy without preeclampsia and without relevant diseases and who signed the informed consent. Table 1 presents the number of cases and controls studied for each gene polymorphism.

We obtained approval for our study protocol from the Ethics Committee of the Faculty of Medicine of the National University of San Marcos and from the ethics committee of the participating hospital. An ad hoc clinical file was filled with mother and newborn data. Written informed consent was obtained from all participants. Blood samples (5 mL) were drawn from the participants' antecubital vein, and the samples were kept in a refrigerator and then transported to the laboratory. The blood samples were subjected to DNA extraction with the commercial kits used for genotype and allele determination for the investigated genes.

The maternal data entered in the ad hoc file were as follows: age, marital status, height, weight, personal medical history (hypertension, previous preeclampsia, diabetes mellitus, neuropathy, cardiopathy, and metabolic syndrome), family medical history (hypertension, diabetes mellitus, obesity, metabolic syndrome, and other conditions), number of pregnancies, preterm deliveries, low-weight newborns, hemoglobin levels, type of delivery, gestational age at delivery, and hospital stay (in days). The newborn data obtained were as follows: weight, Apgar scores at 1 and 5 min, gestational age, complications (fetal distress, respiratory distress, and perinatal asphyxia), IUGR, prematurity, respiratory distress syndrome, jaundice, infection, fetal death, neonatal death, malformations, and hospital stay (in days).

In the genetic molecular analysis, the PCR-RFLP technique was used, specific protocols was employed for each gene, and adequate laboratory conditions were ensured. The genotypes of the polymorphisms were confirmed by automated Sanger sequencing.

VEGF gene +936C/T and +405G/C polymorphisms

The specific primers F: 5'AAGGAAGAGGAGACTCTGCGCAGAGC3' and R: 5´TAAATGTATGTATGTGGGTGGGTGTGTCTACAGG3´ were used for the +936C/T amplification, and the NlaIII enzyme was used for digestion according to the protocol of Papazoglou [29]. For +405G/C, the primers F: 5'CCGACGGCTTGGGGA GATTGCTC3' and R: 5'CGGCGGTCACCCCCAAAAGCAG3' were used for amplification, and the BsmFI enzyme was used for digestion according to the protocol of Banyasz [30] and Garza-Veloz [31].

Figure 1. Determination of the genotypes of the -174 G/C polymorphism in IL6 gene. Left: Agarose gels with homozygous GG (140 and 58 bp) and heterozygous GC (198, 140 and 58 bp) genotypes as determined by PCR-RFLP with SfaNI as the restriction enzyme 32. Right: Chromatograms obtained by automated Sanger sequencing confirming the GG and CC genotypes (marked with arrows).

IL-6 gene -174G/C polymorphism

The specific primers F: 5´TGACTTCAGCTTTAC TCTTTGT'3 and R: 5'CTGATTGGAAACCTTATTAGG'3 were used for amplification, and the restriction enzyme SfaNI was used fo digestion according to Berthold [32]. The GG and GC genotypes obtained by PCR-RFLP and Sanger sequencing are reported in Figure 1.

IL-1β gene -511C/T polymorphism

The specific primers F: 5TGGCATTGATCTGGTTCATC3´ and R: 5´GTTTAGGAATCTTCCCACTT3´ were used for amplification, and the restriction enzyme Aval was used for digestion according to Acosta [28].

Apo A-1 gene -75G/A polymorphism

The specific primers F: 5´AGGGACAGAGCTGATCCTTGAACTCTTAAG3´and R: 5´TTAGGGGACACCTACCCGTCAGGAAGAGCA3´ were used for amplification, and the restriction enzyme Mspl was used for digestion according to Ordovas [33].

Apo B-100 gene 2488C/T (XbaI) polymorphism

The specific primers F: 5´GGAGATATTCAGAAGCTAA3´ and R: 5´GAAGAGCCTGAAGACTGACT3´ were used for amplification, and the restriction enzyme XbaI was used for digestion according to Hu [34].

The data analysis involved the calculation of the allele and genotypic frequencies based on the assumption of the Hardy-Weinberg principle. Moreover, either the chi-square (Ji^2) or he Fisher's exact test was applied to establish the association between genetic polymorphisms and preeclampsia based on $p < 0.05$ and odds ratio (OR). We used IBM SPSS version 22.0, Arlequin version 3.5.2, and a genetic association software in our analysis.

Results

Adding all the participants of the preeclampsia projects between 2012 and 2017, 450 pregnant women were contacted, 22 of whom were excluded because of the following reasons: unmet inclusion criteria for either group, incomplete data, presence of a relevant disease, clotting of blood samples, unwillingness to participate, or failed sample amplification.

The results of allele and genotype frequencies, for the Hardy-Weinberg equilibrium, and for the association and statistical significance are presented in Table 2.

The genotype frequencies of the +936 C/T and +405 G/T variants of the VEGF gene and of the 2488 C/T (XbaI) polymorphism of the APOB100 gene in women with preeclampsia were in Hardy-Weinberg disequilibrium. [a] According to chi-square test or Fisher's exact test.

The genotypic frequencies of the VEGF +936C/T and +405G/C polymorphisms in controls were found to be in Hardy-Weinberg equilibrium; however, in cases they were in disequilibrium, indicating the influence of other factors.

No association was found between genotypes and alleles of the VEGF +936 C/T polymorphism and preeclampsia (p= 0.062 and p= 0.434). The differences between genotypic and allelic frequencies of the VEGF +405 polymorphism in cases and controls were not significant (p= 0.256 and p= 0.356). However, we would like to highlight that the proportions of heterozygous GC (69.2%) and C allele (47.4%) were higher in the preeclamptic women than in the control.

Table 2. Genetic variants in Peruvian pregnant women with preeclampsia and controls.

Gene	Genotypes and alleles	Preeclampsia n (%)	Controls n (%)	OR	95% CI	p [a]
VEGF +936 C/T	CC	19 (42.2)	19 (38.8)	Reference		0.062
	CT	12 (26.7)	23 (46.9)	0.523	0.203-1.341	
	TT	14 (31.1)	7 (14.3)	2.000	0.661-6.056	
	C	50 (55.6)	61 (62.2)	Reference		0.434
	T	40 (44.4)	37 (37.8)	1.319	0.736-2.362	
+405 G/C	GG	7 (17.0)	15 (33.3)	Reference		0.256
	GC	27 (69.2)	24 (53.4)	2.411	0.842-6.904	
	CC	5 (12.8)	6 (13.3)	1.786	0.403-7.906	
	G	41 (52.6)	54 (60.0)	Reference		0.356
	C	37 (47.4)	36 (40.0)	1.354	0.734-2.498	
IL6 -174 G/C	CC	4 (20.0)	13 (33.3)	Reference		0.004
	CG	7 (35.0)	23 (59.0)	0.989	0.243-4.028	
	GG	9 (45.0)	3 (7.7)	9.750	1.744- 54.525	
	C	15 (37.5)	49 (62.8)	Reference		0.011
	G	25 (62.5)	29 (37.2)	2.816	1.281-6.191	
IL1B -511 C/T	CC	30 (61.2)	29 (58.0)	Reference		0.946
	CT	18 (36.7)	20 (40.0)	0.870	0.385-1.968	
	TT	1 (2.1)	1 (2.0)	0.967	0.058-16.192	
	C	78 (79.6)	78 (78.0)	Reference		0.863
	T	20 (20.4)	22 (22.0)	0.909	0.460-1.798	
APOA1 -75 G/A	GG	13 (27.7)	12 (26.7)	Reference		0.832
	GA	23 (48.9)	20 (44.4)	1.062	0.396-2.849	
	AA	11 (23.4)	13 (28.9)	0.781	0.254-2.400	
	G	49 (52.1)	44 (48.9)	Reference		0.768
	A	45 (47.9)	46 (51.1)	0.878	0.493-1.566	
APOB100 2488 C/T (XbaI)	X-X- (CC)	28 (59.6)	25 (55.6)	Reference		0.676
	X- X+ (CT)	12 (25.5)	15 (33.3)	0.714	0.282-1.813	
	X+X+ (TT)	7 (14.9)	5 (11.1)	1.250	0.352-4.442	
	X-	68 (72.3)	65 (72.2)	Reference		0.883
	X+	26 (27.7)	25 (27.8)	0.994	0.521-1.896	

The genotype frequencies of the +936 C/T and +405 G/T variants of the VEGF gene and of the 2488 C/T (XbaI) polymorphism of the APOB100 gene in women with preeclampsia were in Hardy-Weinberg disequilibrium. a According to chi-square test or Fisher's exact test.

As regards the allelic and genotypic frequencies of the IL-6 -174 G/C polymorphism, in Hardy-Weinberg equilibrium, showed different distribution patterns between the preeclamptic women and the controls. Under a codominant model, the GG genotype (OR= 9.750, IC 95%: 1.744-54.525, p= 0.004, with CC genotype as reference) and the G allele (OR= 2.816, IC 95%: 1.281-6.191, p= 0.011, with C allele as reference) are considered to be at risk and with significant differences, wherein the frequencies were higher in the cases than in the controls.

Regarding the -511C/T polymorphism of the IL-1β gene, no significant differences were found in the frequencies of the TT and CT+CC genotypes between the cases and the controls (p >0.946). The homozygous TT was the most frequent genotype (over 50%) in both groups. For the C and T alleles, the differences were not significant (p= 0.863).

The genotypic frequencies of the ApoA-1 -75G/A polymorphism in cases and controls were in Hardy-Weinberg equilibrium, as were the controls for the ApoB100 2488C/T (XbaI) polymorphism; however, preeclamptic pregnant women were in disequilibrium. Overall, genotype and allele frequencies for both ApoA-1 -75G/A and ApoB100 2488C/T (XbaI) polymorphisms, between cases and controls, did not show significant differences (p >0.05) and were not associated with preeclampsia.

Discussion

The cause of preeclampsia remains unknown, and no methods can prevent or treat this disease. Moreover, this obstetric complication may appear unexpectedly in any pregnant woman[3].

An association was observed between preeclampsia and family history of pregnant women, and a genetic factor is considered to be involved in its origin. Until 2012, 178 genes associated with preeclampsia had been described[35]. In 2014, from among over 22 million PubMed records, 28,000 articles related to preeclampsia were found, including 729 articles about 535 genes and genetic variants with a "significant" association with preeclampsia[36].

Specific gene polymorphisms, including angiogenic and antiangiogenic factor genes, have been described in pregnant women with preeclampsia. One angiogenic factor is VEGF, which plays a crucial role in vasculogenesis and vascular permeability. It is usually expressed at optimal levels following an adequate blastocyst placentation[37,38]. VEGF is genetically regulated; some allelic variations of which are possibly associated with preeclampsia, and some of its polymorphisms function as hypoxia-induced factors that play a role in preeclampsia[37]. When placentation is defective, such as in preeclampsia and IUGR, VEGF levels are low[39]. A decrease in VEGF levels may result in placental oxidative stress[40]. Studies have attempted to determine the relationship between VEGF polymorphisms and preeclampsia[41,42], and some studies have associated these polymorphisms with endothelial dysfunction[43,44], preeclampsia severity[45], or HELLP syndrome[46]. The association of some VEGF gene polymorphisms[(,30], such as +936C/T, with preeclampsia has also been reported[30,31].

However, no association of the VEGF +936C/T and +405G/C polymorphisms with preeclampsia was observed in the studied Peruvian pregnant women (p= 0.062 for +936C/T and p= 0.256 for +405G/C). In the +936C/T polymorphism, the mutant homozygous genotype TT was more frequent in the cases, whereas the heterozygous CT genotype was more frequent in the controls. The differences in the frequencies of C and T alleles in the cases and controls were not significant (p= 0,434), for the genotypes as well, but close to the limits of significance (p=0,062). In terms of the VEGF +405 polymorphism, the proportions of heterozygous GC (69.2%) and C allele (47.4%) were higher in the preeclamptic women than in the controls.

Some studies, such as those of Shim[47] and Papazoglou[29], have reported an association between VEGF polymorphisms and preeclampsia. By contrast, other researchers have found no association of preeclampsia with VEGF +936C/T polymorphism[48]; with +813C allele[49]; with

VEGF rs699947, rs1570360, rs2010963, and rs25648 minor alleles [30]; with eNOS and DDAH genes [50]; and with VEGF -2578C/A, -634G/C, and 936C/T alleles. The 936C/T allele has been associated only with severe preeclampsia [45]. In Latin America, Sandrim et al.[51], have found an association of the – C2578A, -1154G, and -634C haplotypes with preeclampsia prevention, and a similar association with the C-2578A allele was found by Cunha et al. [48]; both studies were conducted in Brazil. However, in Ecuador, Sandrim's group has not found such an association with VEGF C2578A and G634C in the same way that Chedraui et al. [44], have not found the said association with the VEGF -2578 C/A, -1498 C/T, -1154 A/G, -634 C/G, and -936C/T polymorphisms [7].

Alterations in inflammatory cytokine and lipid profiles have been associated with the presence and severity of hypertensive disorders of pregnancy [28,52]. Cytokines are proteins secreted by innate or adaptive immune cells, many of the functions of which are mediated by cytokines [53]. The placenta expresses various pro- and anti-inflammatory cytokines, adipokines, and cytokine-like angiogenic growth factors. However, their production of these markers is altered in preeclampsia, at least partially due to hypoxia. It is postulated that endothelial dysfunction underlies the disease manifestations of preeclampsia [54]. Endothelial cell activation seems related to impaired maternal immune response, placental ischemia [55], oxidative stress, and generation of inflammatory cytokines[56].

One class of cytokines are ILs, which modify biological responses. The cytokines involved in the pathophysiology of preeclampsia [11,57,58] include IL-6 [59], IL-1β [60-62], IL-17, and IL-35 [63]. Increased stress during pregnancy is a predictor of an elevated production of IL-1β and IL-6 pro-inflammatory cytokines by lymphocytes during the third trimester. This alteration in the cell function of the immune system increases the risk of preeclampsia and preterm delivery [64]. Moreover, having a female fetus is associated with low levels of pro-inflammatory IFNγ and IL-12 cytokines in the first trimester and with increased levels of pro-inflammatory IL-1β and TNFβ, anti-inflammatory IL-4r, and regulatory IL-5 and IL-10 cytokines in the second trimester [65]. Fetal sex is thus related to the variability in cytokine levels.

IL-6 is a cytokine produced by many innate immune cells, neutrophils, and monocytes/macrophages, and it is expressed during states of cellular stress, such as inflammation, infection, wound, and cancer [66]. IL-6 is an important mediator of acute-phase immune response and of trophoblast proliferation, invasion, and differentiation [67,68]. Studies have suggested that the IL-6 -174 promoter polymorphism is a major genetic regulator in the etiology of early-onset preeclampsia [69-73]. A systematic review that included 73 articles and analyzed 57 unique markers has found that the proinflammatory markers IL-6, IL-8, and tumor necrosis factor alpha have garnered the most support as the potential inflammatory markers for the clinical surveillance of preeclampsia, particularly during the second and third trimesters [58].

However, conflicting results in relation to the role of circulating IL-6 in preeclampsia have been found [69]. In Latin America, the Brazilian study conducted by Pinheiro et al. [72], has found an association of the IL-6 -174G/C allele with protection for preeclampsia; however, another Brazilian study conducted by Daher et al. [73], and a Mexican study by Valencia et al. [(,74], have found no association of this allele with the risk of preeclampsia. Our study on the -174G/C polymorphism of the IL-6 gene showed an association of preeclampsia risk with the GG genotype and the G allele in the preeclamptic Peruvian women. However, these results must be verified in a larger population.

IL-1 is secreted by macrophages, endothelial cells, and some epithelial cells, and it activates endothelial cell inflammation and coagulation. IL-1β gene polymorphisms have been associated with preeclampsia [62,63], preterm birth [75], and recurrent pregnancy loss [76]. In their Brazilian study, Leme et al. [77], have found an association of preeclampsia risk with the IL-1β rs1143630 T allele, while Pontillo et al. [78], who also conducted their study in Brazil, have found no association of IL1β rs1143634 with preeclampsia risk, a finding similar to

that of other studies [79]. The -511 C/T polymorphism in the IL-1β gene promoter region is implicated in the differential production of cytokines. Moreover, it may be associated with the immune inflammatory response in obesity, dyslipidemia, cardiopathy, cancer, infections, and treatment with nutrients and drugs. The IL-1β gene -511C/T polymorphism has also been studied in Peruvian Mestizo, Amazonian, and Andean subpopulations [28], and the T mutant allele associated with an increased cytokine production was frequently observed in these subpopulations. In our study, no significant difference in frequency distribution of the IL-1β gene -511C/T polymorphism TT and CT+CC genotypes between cases (n= 49) and controls (n= 50) was found.

Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoproteins (apo-), constituents of the various lipoprotein classes [80]. Apolipoproteins regulate protein metabolism by transporting and redistributing lipids to cells and tissues. Lipoprotein A (LpA) is a low-density lipoprotein (LDL) particle modified with an apolipoprotein A (Apo A-1), the main component of the structural particles of high-density lipoprotein (HDL), which exhibits anti-inflammatory properties, inhibits LDL oxidation, and clears up excess cholesterol from macrophages [81,82]. Apo A-1 also protects the trophoblast-endothelial cell integration in the presence of a pro-inflammatory stimulus. Women with preeclampsia have low Apo A-1 levels, which deter their ability to control LDL and inflammation [83,84]. Apo B-100 represents the Apo B particles circulating in the body, and it is an LDL. The Apo B-100/Apo A-1 quotient has been proposed as a reliable parameter used to predict atherosclerosis and mortal events resulting from cardiovascular disease that is linked to lipid alterations [85].

Apo A-1 concentrations have been found to increase in normal pregnancy and to decrease in women with preeclampsia [84]; thus, Apo A-1 concentrations are an important risk factor for atherosclerosis among preeclamptic women [86]. Other researchers have found lower levels of Apo A-1 only in patients with severe preeclampsia [87]. Apo B is considered a measure of atherogenic lipoproteins, and it can be used to predict the risk of atherosclerotic cardiovascular disease [88]. However, no difference in Apo A-1 and Apo B levels was observed between preeclamptic and normal pregnant women [87,89]. In our study on Apo A-1 and Apo B-100 genes, no significant differences in genotypes and alleles were found between the women with severe preeclampsia and the controls.

A higher Apo B/Apo A-1 ratio has been associated with an increased risk of preeclampsia [90]. Timur et al. [91], have reported that preeclamptic patients display significantly low Apo A-1 levels and a high Apo B-100/Apo A-1 ratio and that they consider these parameters as useful markers. By contrast, Kharb et al. [92], have found that the serum and cord blood Apo A-1 and Apo B levels were lower in preeclamptic women than in normotensive pregnant women. We have found controversies in the literature regarding the levels of Apo A-1 and Apo B-100 and regarding the possible association of the Apo A-1/Apo B-100 ratio with preeclampsia. Nevertheless, studies have found an association of these gene polymorphisms with cardiovascular disease [93], dyslipidemia [94], osteonecrosis [95], and other disorders.

In this study, the Hardy-Weinberg disequilibrium of the genotype frequencies of the two polymorphisms of the VEGF gene as well as of the Apo B-100 gene in preeclamptic women may indicate population admixture and/or specific characteristics of the patients. However, the lack of association with preeclampsia was corroborated by the Armitage trend test, the result of which is valid even when the frequencies depart from the Hardy-Weinberg equilibrium.

The search for susceptibility genes has led to a drastic increase in the number of published studies associating genetic factors with preeclampsia. However, attempts to replicate the findings of these studies have produced inconsistent results, except for the genes ACE, CTLA4, F2, FV, LPL, and SERPINE1 [96].

Conclusions

The present study analyzed polymorphisms related to endothelial function, angiogenesis, immunological and inflammatory processes, and metabolic syndrome in Peruvian preeclamptic women. No association was found between the genetic markers studied and preeclampsia. However, the -174G/C polymorphism in the IL-6 gene presented significant differences mainly for the GG genotype and the G allele, whose frequencies were higher in the cases with respect to the controls; according to OR calculations, they would be risk factors. The limitation of the study of this polymorphism is the number of case samples (n=20), which should be a stimulus for further studies.

The contradictory results of the work can be partially explained by the genetic composition of the Peruvian population. Lima, the Peruvian city where the study was carried out, has a mixed population, characterized by a high Amerindian component, around 70%, and by European, Asian and African ancestry [97]. Therefore, genetic ancestry and other variables, such as the sex of the fetus, can be considered in future research.

The present study contributes to a better understanding of the genetics of preeclampsia in Peru. Further research is needed to include larger populations of pregnant women and other Peruvian regions, as well as to comprise additional genes related to preeclampsia, a polygenic disorder.

References

1. Mustafa R, Ahmed S, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012; 2012:105918. doi: 10.1155/2012/105918.

2. American College of Obstetricians and Gynecologists. ACOAG issues updated hypertension guidance, discusses new ACC/AHA criteria. ACOG; 2018. https://www.acog.org/news/news-releases/2018/12/acog-issues-updated-hypertension-guidance

3. Pacheco J, Wagner P, Williams MA, Sánchez S. Enfermedades hipertensivas en la gestación. In: Pacheco J. Ginecología, Obstetricia y Reproducción. 2ª Edición. Lima: REP SAC. 2007:1097-130

4. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019; 366: l2381. doi: 10.1136/bmj.l2381.

5. Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham Jr MW, Wallace K, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond). 2016; 130(6): 409-19. doi:10.1042/CS20150702.

6. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014; 5: 372. doi: 10.3389/fphys.2014.00372.

7. Tomoya MR, de Lima Kaminski V, Bogo Chies JÁ. Genetic variants in preeclampsia: lesson from studies in Latin-American populations. Front Physiol. 2018; 9: 1771. doi: 10.3389/fphys.2018.01771.

8. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. Obstet Gynecol. 2019; 133(1): e1-e25.

9. Williams P, Broughton F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011; 25(4-4): 405-17. DOI: 10.1016/j.bpobgyn.2011.02.007.

10. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: Making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta. 2014; 35(Suppl): S20-5. doi:10.1016/j.placenta.2013.12.008.

11. Cindrova-Davies T, Fogarty NME, Jones CJP, Kingdom J, Burton GJ. Evidence of oxidative stress-induced senescence in mature, postmature and pathological human placentas. Placenta. 2018; 68: 15-22. doi: 10.1016/j.placenta.2018.06.307.

12. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble FMS-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895-903. doi:10.1210/jc.2004-1955.

13. Bokslag A, vsn Weissenbruch M, Mol BW, de Groot CJM. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 2016; 102: 47-50. DOI: 10.1016/j.earlhumdev.2016.09.007.

14. Gastrich MD, Zinonos S, Bachmann G, Cosgrove NM, Cabrera J, Cheng JQ, et al. Preeclamptic women are at significantly higher risk of future cardiovascular outcomes over a 15-year period. J Women´s Health. 2020; 29(1): 74-83. Doi: 10.1089/jwh.2019.7671.

15. Aukes AM, De Groot JC, Wiegman MJ, Aarnoudse JG, Sanwikarja GS, Zeeman GG. Long-term cerebral imaging after pre-eclampsia. BJOG. 2012; 119(9): 1117-22. doi:10.1111/j.1471-0528.2012.03406.x.

16. McBryde M, Fitzallen GC, Liley HG, Taylor HG, Bora S. Academic outcomes of school-aged children born preterm. A systematic review and meta-analysis. JAMA Network Open. 2020; 3(4): e202027. doi:10.1001/jamanetworkopen.2020.2027.

17. Sun BZ, Moster D, Harmon QE, Wilcox AJ. Association of preeclampsia in term births with neurodevelopmental disorders in offspring. JAMA Psychiatry. 2020; 77(8):823-829. doi:10.1001/jamapsychiatry.2020.0306.

18. Pacheco J. Del Editor sobre la publicación de una aproximación bioinformática a la genética de la preeclampsia. Re Peru Ginecol Obstet. 2014; 60(2): 105-7. Doi: 10.31403/rpgo.v60i119.

19. Sahin H, Gunel T, Benian A, Ucar EA, Guralp O, Kilic A. Genomic and proteomic investigation of preeclampsia. Experim Ther Med. 2015; 10: 711-6. DOI: 10.3892/etm.2015.2509.

20. Harmon QE, Engel SM, Wu MC, Moran TM, Luo J, Stuebe AM, et al. Polymorphisms in inflammatory genes are associated with term small for gestational age and preeclampsia. Am J Reprod Immunol. 2014; 71(5): 472-84. doi: 10.1111/aji.12241.

21. Karumanchi SA. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension. 2016; 67: 1072-9. doi:10.1161/HYPERTENSIONAHA.116.06421.

22. Honigberg MC, Cantonwine DE, Thomas AM, Lim KH, Parry SI, McElrath TF. Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol. 2016; 36(3): 172-7. doi: 10.1038/jp.2015.170.

23. Gene. PGF Placental growth factor [Homo sapiens (human)]. Gene ID: 5228, updated on 24-Nov-2020. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5228

24. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med. 2011; 24(10): 1187-207. DOI: 10.3109/14767058.2011.589932

25. Roberts JM, Rajakumar A. Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab. 2009; 94(7): 2252-4. doi: 10.1210/jc.2009-0945.

26. Barden AE, Herbison CE, Beilin LJ, Michael CA, Walters BN, Van Bockxmeer FM. Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens. 2001; 19(10): 1775-82. DOI: 10.1097/00004872-200110000-00011

27. Aggarwal PK, Jain V, Srinivasan R, Jha V. Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. J Hypertens. 2009; 27(10): 2044-50. DOI: 10.1097/HJH.0b013e32832f7f3f

28. Acosta O, Solano L, Huerta D, Oré D, Sandoval J, Figueroa J, et al. Variabilidad genética de la respuesta inflamatoria. I. Polimorfismo -511 C/T en el gen IL1ß en diferentes subpoblaciones peruanas. An fac med. 2012;73(3):221-5. DOI: 10.15381/anales.v73i3.868.

29. Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2004; 10(5):321-4. DOI: 10.1093/molehr/gah048

30. Bányász I, Szabo S, Bokodi G, Vannay A, Vasarhelyi B, Szabo A, et al. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod. 2006; 12(4): 233-6.

31. Garza-Veloz I, Castruita-De La Rosa C, Cortes-Flores R, Martínez-Gaytan V, Rivera-Muñoz JE, Garcia-Mayorga EA, et al. No association between polymorphisms/haplotypes of the vascular endothelial growth factor gene and preeclampsia. BMC Pregnancy and Childbirth. 2011; 11: 35. doi: 10.1186/1471-2393-11-35.

32. Berthold HK, Laudes M, Krone W, Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One. 2011; 6(9): e24719. Doi: 10.1371/journal.pone.0024719

33. Ordovas J, Corella D, Cupples L, Demissie S, Kelleher A, Coltell O, et al. Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr. 2002; 75(1): 38-46. DOI: 10.1093/ajcn/75.1.38

34. Hu P, Qin Y, Jing C, Lu L, Hu B, Du P. Effect of apolipoprotein B polymorphism on body mass index, serum protein and lipid profiles in children of Guangxi, China. Ann Hum Biol. 2009; 36(4): 411-20. doi:10.1080/03014460902882475

35. Jebbink J, Wolters A, Fernando F, Afink G, van der Post J, Ris-Stalpers C. Molecular genetics of preeclampsia and HELLP syndrome - A review. Biochim Biophys Acta. 2012; 1822(12): 1960-9. DOI: 10.1016/j.bbadis.2012.08.004

36. Triche EW, Uzun A, DeWan AT, Kurihara I, Liu J, Occhiogrosso R, et al. Bioinformatic approach to the genetics of preeclampsia. Obstet Gynecol. 2014; 123(6): 1155- 61. DOI: 10.1097/AOG.0000000000000293

37. Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009; 22(5):371-8. DOI: 10.1080/14767050802645035.

38. Gómez CLM. Actualización en la fisiopatología de la preeclampsia. Rev Peru Ginecol Obstet. 2014;60(4):321-32. DOI: 10.31403/rpgo.v60i156

39. Mateus J. Significancia del desbalance de los factores angiogénicos en preeclampsia. Rev Peru Ginecol Obstet. 2014;60(4):33-44. DOI: 10.31403/rpgo.v60i157

40. Kweider N, Fragoulis A, Rosen C, Pecks U, Rath W, Pufe T, et al. Interplay between vascular endothelial growth factor (VEGF) and the nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia. J Biol Chem. 2011; 286(50): 42863-72. DOI: 10.1074/jbc.M111.286880

41. Song GG, Kim JH, Lee YH. Associations between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: a meta-analysis. Immunol Invest. 2013;42(8):749-62. doi: 10.3109/08820139.2013.

42. Cheng D, Hao Y, Zhou W, Ma Y. Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: a meta-analysis. PLoS One. 2013; 8(11): e78173. doi: 10.1371/journal.pone.0078173.

43. Luizon MR, Palei AC, Sandrim VC. Polymorphisms and haplotypes in candidate genes related to angiogenesis and endothelial dysfunction in preeclampsia. J Pregnancy. 2012; 2012: 914704. doi: 10.1155/2012/914704.

44. Chedraui P, Solis EJ, Bocci G, Gopal S, Russo E, Escobar GS, Hidalgo L, et al. Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. J Matern Fetal Neonatal Med. 2013; 26(3): 226-32. doi: 10.3109/14767058.2012.733760

45. Procopciuc LM, Caracostea G, Zaharie G, Stamatian F. Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile. J Matern Fetal Neonatal Med. 2014; 27(17):1754-60. doi: 10.3109/14767058.2014.942625.

46. Haram K, Mortensen JH, Nagy B. Genetic aspects of preeclampsia and the HELLP syndrome. J Pregnancy. 2014; 2014: 910751. doi: 10.1155/2014/910751

47. Shim JY, Jun JK, Jung BK, Kim SH, Won HS, Lee PR, et al. Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol. 2007;197(3):271.e1-4.

48. Cunha VM, Grecco RL, Paschoini MC, Silva SR, Ruiz MT, Balarin MA. Polimorfismos genéticos do fator de crescimento do endotélio vascular na pré-eclâmpsia. Rev Bras Ginecol Obstet. 2011; 33(7): 158-63.

49. Atis A, Oruc O, Aydin Y, Cetincelik U, Goker N. Vascular endothelial growth factor gene +813CC polymorphism of foetus is associated with preterm labour but not with pre-eclampsia in Turkish pregnant women. Int J Immunogenet. 2012; 39(3): 241-6.

50. Kim YJ, Park BH, Park H, Jung SC, Pang MG, Ryu HM, et al. No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations. Twin Res Hum Genet. 2008; 11(1): 77-83. DOI: 10.1375/twin.11.1.77

51. Sandrim VC, Palei ACT, Cavalli RC, Araújo FM, Ramos ES, Duarte G, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod. 2009; 15: 115-120. doi: 10.1093/molehr/gan076

52. Wang Y, Shi D, Chen L. Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies. J Clin Hypertens (Greenwich). 2018; 20(2): 394-9. doi:10.1111/jch.13161

53. Abbas AK, Lichtman AH. Inmunología celular y molecular. Madrid, España: Elsevier Science; 2004. 243-74.

54. Khong TY, Robertson WB. Spiral artery disease. In: Coulam CB, Faulk WP, McIntyre JA, eds. Immunological obstetrics. New York; Norton. 1992: 492-501.

55. Taylor RN, Roberts JM. Endothelial cell dysfunction. In: Lindheimer MD, Roberts JM, Cunningham GF, eds. Chesley´s hypertensive disorders in pregnancy, 2nd Ed. Stamford: Appleton & Lange; 1999. 395-429.

56. Gilbert JS, Ryan MJ, Lamarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol. 2008;294(2):H541-H550.

57. Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Prin Pract. 2013; 22(Suppl 1): 8-19. doi: 10.1159/000354200

58. Black KD, Horowitz JA. Inflammatory markers and preeclampsia: A systematic review. Nurs Res. 2018;67(3):242-51. doi:10.1097/NNR.0000000000000285

59. Zhang Z, Gao Y, Zhang L, Jia L, Wang P, Zhang L, et al. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. Hypertens Pregnancy. 2013; 32(3):270-80. doi: 10.3109/10641855.2013.2013.798332

60. Lachmeijer AMA, Nosti-Escanilla MP, Bastiaans EB, Sandkuijl LA, Kostense PJ, Aarnoudse JG, et al. Linkage and association studies of IL1B and IL1RN gene polymorphisms in preeclampsia. Hypertens Pregnancy. 2002;21(1):23-38. DOI: 10.1081/PRG-120002907

61. Farnaz MF, Afshari JT, Rezaieyazdi Z, Ghomian N. Association of single nucleotide polymorphisms in the human tumor necrosis factor-a and interleukin 1-b genes in patients with pre-eclampsia. Iran J Allergy Asthma Immunol. 2012; 11(3): 224-9.

62. Wang X, Jiang F, Liang Y, Xu L, Li H, Liu Y, et al. Interleukin-1ß-31C/T and -511T/C polymorphisms were associated with preeclampsia in Chinese Han population. PLoS One. 2014; 9(9): e106919. doi: 10.1371/journal.pone.0106919

63. Ozkan ZS, Simsek M, Ilhan F, Deveci D, Godekmerdan A, Sapmaz E. Plasma IL-17, IL-35, interferon-?, SOCS3 and TGF-ß levels in pregnant women with preeclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med. 2014; 27(15): 1513-7. doi: 10.3109/14767058.2013.861415

64. Coussons-Read ME, Okun ML, Nettles CD. Psychosocial stress increases inflammatory markers and alters cytokine production across pregnancy. Brain Behav Immun. 2007; 21(3): 343-50. doi:10.1016/j.bbi.2006.08.006.

65. Taylor BD, Ness RB, Klebanoff MA, Tang G, Roberts JM, Hougaard DM, e al. The impact of female fetal sex on preeclampsia and the maternal immune milieu. Pregnancy Hypertens. 2018; 12:53-7. doi: 10.1016/j.preghy.2018.02.009

66. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis. J Scleroderma Related disorders. J Scleroderma Related Disorders. 2017; 2(2 suppl): S1-S5. Doi: 10.5301/jsrd.5000265

67. LaMarca B, Brewer J, Wallace K. IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate. Int J Interferon Cytokine Mediator Res. 2011; 2011(3):59-64. doi:10.2147/IJICMR.S16320

68. Barbosa deLT, Sass N, Mattar R, Moron AF, Torloni MR, Franchim CS, et al. Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypert Res. 2009; 32: 565-9. Doi: 10.1038/hr.2009.58

69. Sowmya S, Ramaiah A, Nallari P, Jyothy A, Venkateshwari A. Role of IL-6 -174(G/C) promoter polymorphism in the etiology of early-onset preeclampsia. Inflamm Res. 2015; 64(6): 433-9. doi: 10.1007/s00011-015-0823-z

70. Fan DM, Wang Y, Liu XL, Zhang A, Xu Q. Polymorphisms in interleukin-6 and interleukin-10 may be associated with risk of preeclampsia. Genet Mol Res. 2017; 16(1): gmr16018588. doi: 10.4238/gmr16018588

71. Puppala M, Kalpana VL, Aniradha A, Shusma M, Sudhakar G, Polipalli SK. Association of tumor necrosis factor-alpha and interleukin-6 gene polymorphisms with preeclampsia. Int J Bioassays. 2016; 5(02): 4774.

72. Pinheiro MB, Gomes KB, Ronda ARSC, Guimaraes GG, Freitas LG, Teixeira-Carvalho A, et al. Severe preeclampsia: Association of genes polymorphisms and maternal cytokines production in Brazilian population. Cytokine. 2014; 71: 232-7. Doi: 10.1016/j.cyto.2014.10.021

73. Daher S, Sass N, Oliveira LG, Mattar R. Cytokine genotyping in preeclampsia. Am J Reprod Immunol. 2006; 55: 130-135. doi: 10.1111/j.1600-0897.2005.00341.x

74. Valencia VEY, Canto-Cetina T, Romero AJF, Coral-Vázquez RM, Canizales-Quinteros S, Coronel A, et al. Analysis of polymorphisms in interleukin-10, interleukin-6, and interleukin-1 receptor antagonist in Mexican-Mestizo women with pre-eclampsia. Genet Test Mol Biomarkers. 2012; 16: 1263-1269. doi: 10.1089/gtmb.2012.0181

75. Schmid M, Haslinger P, Stary S, Leipold H, Egarter C, Grimm C. Interleukin-1 beta gene polymorphisms and preterm birth. Eur J Obstet Gynecol Reprod Biol. 2012; 165(1): 33-6. doi: 10.1016/j.ejogrb.2012.07.013.

76. Nair RR, Khanna A, Singh K. Association of interleukin 1 receptor antagonist (IL1RN) gene polymorphism with recurrent pregnancy loss risk in the North Indian Population and a meta-analysis. Mol Biol Rep. 2014; 41(9): 5719-27. doi: 10.1007/s11033-014-3443-8.

77. Leme GLP, Menezes FE, Mendonca C, Barreto I, Alvim-Pereira C, Alvim-Pereira F, et al. Analysis of association of clinical aspects and IL1B tagSNPs with severe preeclampsia. Hypertens Pregnancy. 2016; 35: 112-122. doi: 10.3109/10641955.2015.1116554

78. Pontillo A, Reis EC, Bricher PN, Vianna P, Diniz S, Fernandes KS, et al. NLRP1 L155H polymorphism is a risk factor for preeclampsia development. Am J Reprod Immunol. 2015; 73: 577-581. doi: 10.1111/aji.12353

79. Kang L, Chen C-H, Yu C-H, Chang C-H, Chang F-M. Interleukin-1ß gene is not associated with preeclampsia in Taiwanese. Taiwanese J Obtet Gynecol. 2012; 51(2): 240-4. Doi: 10.1016/j.tjog.2012.04.014

80. Mahley RW, Innerarity TL, Rall Jr SC, Weisgraber KH. Plasma lipoproteins: Apolipoprotein structure and function. J Lipid Res. 1984; 25(12): 1277-94.

81. Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017;12(Suppl 1):31-7. doi:10.1007/s11789-017-0084-1

82. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37(12):2473-91.

83. Charlton F, Bobek G, Stait-Gardner T, Price WS, Mirabito CKM, Xu B, et al. The protective effect of apolipoprotein in models of trophoblast invasion and preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017; 312(1): R40-R48. doi:10.1152/ajpregu.00331.2016

84. Rosing U, Samsioe G, Olund A, Johansson B, Kallner A. Serum levels of apolipoprotein A-I, A-II and HDL-cholesterol in second half of normal pregnancy and in pregnancy complicated by pre-eclampsia. Horm Metab Res. 1989;21(7):376-82. doi: 10.1055/s-2007-1009242

85. Castillo AI, Armas RNB, Dueñas HA, González GOR, Arocha MC, Castillo GA. Riesgo cardiovascular según tablas de la OMS, el estudio Framingham y la razón apolipoproteína B/apolipoproteína A1. Rev Cubana Invest Biomed. 2010; 29(4): 479-88.

86. Bayhan G, Koçyigit Y, Atamer A, Atamer Y, Akkus Z. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. Gynecol Endocrinol. 2005;21(1):1-6. doi:10.1080/09513590500097382

87. Zhang H, Zhang Y, Yang F, Lius S, Xu Z, Wang J, et al. Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia. Mol Biosyst. 2011;7(8):2470-9. doi:10.1039/c1mb05142c

88. Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-54. doi:10.1016/j.pathol.2018.11.006

89. Var A, Kuscu NK, Koyuncu F, Uyanik BS, Onur E, Yildirim Y, Oruç S. Atherogenic profile in preeclampsia. Arch Gynecol Obstet. 2003;268(1):45-7.

90. Serrano NC, Guio-Mahecha E, Quintero-Lesmes DC, Becerra-Bayona S, Paez MC, et al. Lipid profile, plasma apolipoproteins, and pre-eclampsia risk in the GenPE case-control study. Atherosclerosis. 2018; 276:189-94. doi:10.1016/j.atherosclerosis.2018.05.051

91. Timur H, Korkut DH, Kara O, Kirbas A, Inal HA, Gencosmanoglu TG, et al. A study of serum Apo A-1 and Apo B-100 levels in women with preeclampsia. Pregnancy Hypertens. 2016; 6(2):121-5. DOI: 10.1016/j.preghy.2016.04.003

92. Kharb S, Bala J, Nanda S. Markers of obesity and growth in preeclamptic and normotensive pregnant women. J Obstet Gynaecol. 2017;37(5):610-5. doi:10.1080/01443615.2017.1286463

93. Bora K, Pathak MS, Borah P, Hussain I, Das D. Association of the apolipoprotein A-I gene polymorphisms with cardiovascular disease risk factors and atherogenic indices in patients from Assam, Northeast India. Balkan J Med Genet. 2017; 20(1):59-70. doi: 10.1515/bjmg-2017-0002

94. Ou HJ, Huang G, Liu W, Ma XL, Wei Y, Zhou T, et al. Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia. Genet Mol Res. 2015;14(3):9277-90. doi:10.4238/2015. August.10.8

95. Chen L, Wei P, Jiang K, Xia XX. Apolipoprotein A1 and neuronal nitric oxide synthase gene polymorphisms and hormone-related osteonecrosis of the femoral head. Eur Rev Med Pharmacol Sci. 2017;21(14):3159-63.

96. Buurma AJ, Turner RJ, Driessen JHM, Mooyaart AL, Schoones JW, Bruijn JA, Bloemenkamp KWM, Dekkers OM, Baelde HJ. Genetic variants in pre-eclampsia: a meta-analysis, Hum Reprod Update. 2013; 19(3):289-303. doi: 10.1093/humupd/dms060

97. Sandoval J, Salazar-Granara A, Acosta O, Castillo-Herrera W, Fujita R, Pena SDJ, et al. Tracing the genomic ancestry of Peruvians reveals a major legacy of pre-Columbian ancestors. J Hum Genet 2013; 58(9):627-34. doi: 10.1038/jhg.2013.73.